John Peppin
Internal Medicine · Cynthiana, KYNPI 1649262635
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $99,031 of the $107,819 with a category attached, or 91.8%. Endo Pharmaceuticals Inc. accounts for 86.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $105,595 and has fallen 99.6% since, to $436 in 2025. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $1283.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$93K
- GRT US Holding, Inc.$13K
- MDD US Operations, LLC$700
- Biodelivery Sciences International, Inc.$327
- Axsome Therapeutics, Inc.$227
- Acelrx Pharmaceuticals, Inc.$128
- plus $842 from 19 others
Across 12 payments — averaging $5041.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- MDD US Operations, LLC$60K
What the payments were for
- Consulting fees$99,03192%
- Speaking & faculty fees$3,0003%
- Travel & lodging$3,5793%
- Food & beverage$2,2092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 5 | $92,884 |
| GRT US Holding, Inc. | 23 | $12,711 |
| MDD US Operations, LLC | 4 | $700 |
| Biodelivery Sciences International, Inc. | 2 | $327 |
| Axsome Therapeutics, Inc. | 6 | $227 |
| Acelrx Pharmaceuticals, Inc. | 2 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| AbbVie | 4 | $76 |
| ANI Pharmaceuticals, Inc. | 4 | $69 |
| Bayer | 3 | $59 |
| Collegium Pharmaceutical, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $47 |
| Alkermes, Inc. | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Novartis | 2 | $38 |
| Exact Sciences | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Avanos Medical | 1 | $22 |
| Biotronik NRO, Inc. | 1 | $20 |
| Merck | 1 | $16 |
| GSK | 1 | $15 |
| Amgen | 1 | $15 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$12,322
- BELBUCA$242
- Auvelity$120
- DSUVIA$110
- Lucemyra/Lofexidine$110
How this compares
$107,819 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 54 | $52,621 |
| OzempicSemaglutide | 42 | $45,991 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $34,449 |
| XareltoRivaroxaban | 17 | $23,693 |
| EliquisApixaban | 28 | $19,738 |
| MyrbetriqMirabegron | 21 | $18,560 |
| MounjaroTirzepatide | 18 | $18,330 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $15,030 |
| LinzessLinaclotide | 19 | $14,934 |
| Oxycodone Hcl | 334 | $8,277 |
| JanuviaSitagliptin Phosphate | 15 | $8,140 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 346 | $7,400 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 297 | $6,973 |
| Gabapentin | 650 | $6,584 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $5,085 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $15 | $49,48084 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $18,56021 claims |
| AbbVieLinzess, Synthroid | $76 | $15,66635 claims |
| MerckJanuvia | $16 | $8,14015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Cynthiana
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
- Sanjiv GuptaGrayson$49K
- Kelley McIntyreLouisville$48K
- Justin CaseFlorence$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.